7th Annual Allogeneic Cell Therapies Summit

Start: Tuesday, June 10, 2025 9:00AM
End: Thursday, June 12, 2025 6:00PM

As the autoimmune wave breathes financial life back into the allogeneic space, and a growing number of oncology pipelines entering the clinic, it is now business critical that allogeneic drug developers prove the potential of the off-the-shelf approach to enable reduced cost of goods and greater access for patients.

As the must-attend meeting for the allogeneic community, the 7th Annual Allogeneic Cell Therapies Summit will address the critical challenges in optimizing complex gene engineering, ensuring safety and potency of off-the-shelf cell therapies to accelerate your path to clinical and commercial success.

Spanning preclinical development through to manufacturing and process development, brainstorm with industry pioneers the best approaches for developing preclinical assays, targeting novel cell types and streamlining automated manufacturing processes to support scale-up for larger patient populations.

Covering disease indications in both oncology and autoimmunity, connect with expert speakers from Adicet Bio, Caribou Bioscience, IN8Bio and more, as they share innovations in non-viral engineering and manufacturing, the latest advancements in cell expansion techniques and benchmark new donor retention strategies for a smoother journey to the clinic and beyond!

URLs:
Tickets: https://go.evvnt.com/2800962-2?pid=3698
Brochure: https://go.evvnt.com/2800962-3?pid=3698

Prices:
Drug Developer Pricing - Conference + 2 Workshops: USD 4197.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3598.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Service Provider Pricing - Conference + 2 Workshops: USD 5197.00,
Service Provider Pricing - Conference + 1 Workshop: USD 4498.00,
Service Provider Pricing - Conference Only: USD 3799.00,
Academic + Start Up Pricing - Conference + 2 Workshops: USD 3597.00,
Academic + Start Up Pricing - Conference + 1 Workshop: USD 3098.00,
Academic + Start Up Pricing - Conference Only: USD 2599.00

Speakers: Ajay Vishwakarma Founder and Chief Executive Officer CellBioEngines, Albert Ribickas BMT Operations Manager Moffitt Cancer Center, Alexey Bersenev Chief Technical Officer CellBioEngines, Amanda Medcalf Conerty Executive Director - Process, Analytical Development and Manufacturing Artiva Biotherapeutics, Inc, Andrew Gilder Senior Process Engineer Shoreline Biosciences, Blake Aftab Chief Scientific Officer Adicet Bio Inc., Brian Garrison Vice President - Research Senti Biosciences Inc., Cecilia Zhang Co-founder and Chief Scientific Officer Biosyngen Group, Cokey Nguyen President and Chief Executive Officer Atara Biotherapeutics Inc., Dan Crowley Chief Executive Officer Remedy Biologics, Enrique Zudaire Senior Vice President - Translational Sciences and Therapeutics Discovery Caribou Biosciences, Gregg Solar Vice President Process Development Shoreline Biosciences, James Adams Chief Technical Officer Tr1x therapeutics, Janet Lambert Advisor Alliance for Regenerative Medicine, Kanya Rajangam President, Head of Research and Development and Chief Medical Officer Senti Biosciences Inc., Karen Aboody Professor City of Hope, Kevin Nishimoto Senior Director - Preclinical Cell and Immunotherapy Research Adicet Bio Inc., Laurent Poirot Senior VP Immunology Cellectis, Leopold Bertea Chief Technology Officer Mendus, Luis Borlado Executive Director Allogeneic Cell Therapy Process Development AstraZeneca, Monica Raimo Director, Product and Process Development Glycostem Therapeutics, Olivier Negre Chief Scientific Officer Smart Immune, Raphael Ognar President, Chief Executive Officer , Co-Founder and Chairman of the Board NKILT Therapeutics, Rashmi Kshirsagar Senior Vice President Be Biopharma, Rui Tostoes Vice President - Chemistry, Manufacturing, and Controls ImmuneBridge, Sadhak Sengupta Senior Director - Research and Development IN8Bio, Shirley M Bartido Director - Global Regulatory Affairs, Cell Therapy Oncology Takeda Pharmaceutical, So-Ching Brazer Executive Director, Regulatory CMC Adicet Bio Inc., Stephen Chen Chief Technical Officer Tevogen Bio, Tim (Tingxi) Guo Senior Scientist GentiBio, Tim Gallagher Chief Business Officer PhosphoGam, Tobias Deuse Co-Founder and Professor at UCSF Shionogi Inc., Tony Arulanandam CEO and Founder Synaptimmune Therapeutics, Vibha Jawa Executive Director Bristol Myers Squibb, Xiaoya Sun Research, Analytical Development and Cell Therapy Investigator Takeda Pharmaceutical